US Patent

US11083733 — Betulin-containing birch bark extracts and their formulation

Formulation · Assigned to Amryt Research Ltd · Expires 2039-01-04 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects birch bark extracts containing triterpenes, specifically betulin, and their formulation into stable pharmaceutical compositions.

USPTO Abstract

The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing.

Drugs covered by this patent

birch-triterpenes (BIRCH TRITERPENES)

Patent Metadata

Patent number: US11083733
Jurisdiction: US
Classification: Formulation
Expires: 2039-01-04
Drug substance claim: No
Drug product claim: Yes
Assignee: Amryt Research Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.